Human Genetics Program, Sanford Children's Health Research Center, Sanford Burnham Medical Research Institute, La Jolla, CA 92037, USA.
Department of Pediatrics, University of Washington, Seattle, WA 98195, USA.
Am J Hum Genet. 2014 Feb 6;94(2):161-75. doi: 10.1016/j.ajhg.2013.10.024.
Over 100 human genetic disorders result from mutations in glycosylation-related genes. In 2013, a new glycosylation disorder was reported every 17 days. This trend will probably continue given that at least 2% of the human genome encodes glycan-biosynthesis and -recognition proteins. Established biosynthetic pathways provide many candidate genes, but finding unanticipated mutated genes will offer new insights into glycosylation. Simple glycobiomarkers can be used in narrowing the candidates identified by exome and genome sequencing, and those can be validated by glycosylation analysis of serum or cells from affected individuals. Model organisms will expand the understanding of these mutations' impact on glycosylation and pathology. Here, we highlight some recently discovered glycosylation disorders and the barriers, breakthroughs, and surprises they presented. We predict that some glycosylation disorders might occur with greater frequency than current estimates of their prevalence. Moreover, the prevalence of some disorders differs substantially between European and African Americans.
超过 100 种人类遗传疾病是由于糖基化相关基因的突变引起的。2013 年,每 17 天就会报告一种新的糖基化疾病。鉴于至少 2%的人类基因组编码聚糖生物合成和识别蛋白,这种趋势可能会持续下去。已建立的生物合成途径提供了许多候选基因,但发现意想不到的突变基因将为糖基化提供新的见解。简单的糖生物标志物可用于缩小外显子组和基因组测序确定的候选基因的范围,并且可以通过对受影响个体的血清或细胞进行糖基化分析来验证这些标志物。模式生物将扩大对这些突变对糖基化和病理学影响的理解。在这里,我们重点介绍了一些最近发现的糖基化疾病以及它们带来的障碍、突破和惊喜。我们预测,一些糖基化疾病的发生频率可能高于目前对其患病率的估计。此外,一些疾病在欧洲裔和非裔美国人之间的患病率存在显著差异。